AI drug discovery market to grow 30% CAGR, to reach US$ 35 bn by 2034; Novo, Lilly, BMS forge deals

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Apranax

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

42 API Suppliers, 23 USDMF, 12 CEP/COS, 1 JDMF, 3 EU WC, 37 KDMF, 12 NDC API, 1 VMF, 19 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

INTERMEDIATES

4 Intermediate Suppliers

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

333 FDF Dossiers, 115 FDA Orange Book, 96 Europe, 25 Canada, 23 Australia, 24 South Africa, 50 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 250MG, TABLET;ORAL - 375MG, TABLET;ORAL - 500MG, SUSPENSION;ORAL - 25MG/ML, TABLET, DELAYED RELEASE;ORAL - 375MG, TABLET, DELAYED RELEASE;ORAL - 500MG, TABLET, DELAYED RELEASE;ORAL - EQ 20MG BASE;375MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 20MG BASE;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

7 Evonik, 1 Rochem International Inc, 6 SPI Pharma, 6 DKSH, 6 Faran Shimi Pharmaceutical, 11 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 6 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 ACG Worldwide, 8 Actylis, 2 Aeon Procare, 2 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 33 BASF, 1 Clariant, 14 Corel Pharma Chem, 6 DFE Pharma, 3 Doshion Polyscience, 2 Finar, 12 Gangwal Chemicals, 13 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 32 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 12 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 3 Novo Excipients, 4 Pharmatrans-Sanaq, 6 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 27 Roquette, 14 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 2 The Dow Chemical Company, 3 Ulanqab Kema New Material, 2 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

72 Coating Systems & Additives, 70 Fillers, Diluents & Binders, 41 Controlled & Modified Release, 38 Disintegrants & Superdisintegrants, 35 Solubilizers, 31 Thickeners and Stabilizers, 29 Direct Compression, 27 Granulation, 24 Film Formers & Plasticizers, 20 Taste Masking, 17 Co-Processed Excipients, 17 Lubricants & Glidants, 16 Topical, 15 Parenteral, 11 Chewable & Orodispersible Aids, 8 Emulsifying Agents, 7 Rheology Modifiers, 6 API Stability Enhancers, 5 Empty Capsules, 5 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

DIGITAL CONTENT

35 News #PharmaBuzz

35 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 83 Regulatory FDF Prices, 1 Annual Reports

MARKET PLACE

33 APIs, 3 FDF Dossiers

REF. STANDARDS & IMPURITIES

3 EDQM, 5 USP, 14 Others

ANALYTICAL

3 BioAnalytical Methods

3 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	VMF No.	Subject	Received Date	Status	Type
08/05/2024	Laboratorio Syntex S.A	Argentina	SYNTEX ANIMAL HEALTH DIVISION OF SYNTEX AGRIBUSINESS INC	3573	Naproxen	1974-02-05	Inactive	II

Apranax

Apranax

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

42 API Suppliers

23 USDMF

12 CEP/COS

1 JDMF

3 EU WC

37 KDMF

12 NDC API

1 VMF

19 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

5 Drugs in Development

INTERMEDIATES

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

333 FDF Dossiers

115 FDA Orange Book

96 Europe

25 Canada

23 Australia

24 South Africa

50 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 250MG

TABLET;ORAL - 375MG

TABLET;ORAL - 500MG

SUSPENSION;ORAL - 25MG/ML

TABLET, DELAYED RELEASE;ORAL - 375MG

TABLET, DELAYED RELEASE;ORAL - 500MG

TABLET, DELAYED RELEASE;ORAL - EQ 20MG BASE;375MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 20MG BASE;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

7 Evonik

1 Rochem International Inc

6 SPI Pharma

6 DKSH

6 Faran Shimi Pharmaceutical

11 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

6 Nanjing Well Pharmaceutical

1 Pfanstiehl

1 ACG Worldwide

8 Actylis

2 Aeon Procare

2 Alcedo Pharmachem

9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

33 BASF

1 Clariant

14 Corel Pharma Chem

6 DFE Pharma

3 Doshion Polyscience

2 Finar

12 Gangwal Chemicals

13 Ideal Cures Pvt Ltd

4 Ingredion Pharma Solutions

32 Kerry

3 Kima Chemical

6 Lonza Capsugel

12 Microlex e.U

1 Nanjing Bold Chemical

2 Nomisma Healthcare

3 Novo Excipients

4 Pharmatrans-Sanaq

6 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

27 Roquette

14 Seppic

6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

12 Sigachi Industries

TABLET, DELAYED RELEASE;ORAL - EQ 20MG BASE;375MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 20MG BASE;500MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons